Three drug companies dominate the U.S. insulin market: Novo Nordisk, Eli Lilly and Sanofi. Last spring, Eli Lilly reported its drugs Humalog and insulin lispro were in short supply.

Lilly said Humalog vials are temporarily out of stock in some U.K. pharmacies due to “the dynamic nature of insulin supply and demand, coupled with a brief delay in manufacturing.” ...

Specifically, three Humalog pens were discontinued in 2012, followed soon by three replacement products. Over the following six years, the average price of a Humalog pen rose by a remarkable 120%.

This applies to the Humalog insulin in vials only – pre-filled pens and cartridges are not affected. The affected vials are Humalog 100u vials, Humulin M3 vials and Humulin S100 vials.

Eli Lilly said the Humalog medication is also available in cartridges and pre-filled multi-dose pens (KwikPen) and there “may be alternative formals of the insulin for patients and health-care ...

Eli Lilly also said that all of its other insulin products — including Humalog and Insulin Lispro injection in prefilled pens — are still available across the U.S. "We recognize that any supply ...

I have an insulin pump. I take like 60 units a day of insulin," Jon Konrad, who lives in Boca Raton, told WPTV. The insulin Konrad uses that connects to his pump is Humalog, made by Eli Lilly.

Eli Lilly said its other insulin products — like Humalog and Insulin Lispro Injection in prefilled pens — are still available throughout the U.S.

Drugmaker Eli Lilly & Co is announcing a temporary shortage of two of its insulin products. "The 10 mL [millilter] vials of Humalog® and Insulin Lispro Injection are or will be temporarily out of ...